{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:31:13Z","timestamp":1768505473180,"version":"3.49.0"},"posted":{"date-parts":[[2023,5,23]]},"group-title":"Immunology","reference-count":71,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,5,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Malaria, caused by\n                  <jats:italic>Plasmodium<\/jats:italic>\n                  parasites, remains one of the most devastating infectious diseases worldwide, despite control efforts that have lowered morbidity and mortality. The only\n                  <jats:italic>P. falciparum<\/jats:italic>\n                  vaccine candidates to show field efficacy are those targeting the asymptomatic pre-erythrocytic (PE) stages of infection. The subunit (SU) RTS,S\/AS01 vaccine, the only licensed malaria vaccine to date, is only modestly effective against clinical malaria. Both RTS,S\/AS01 and the SU R21 vaccine candidate target the PE sporozoite (spz) circumsporozoite (CS) protein. These candidates elicit high-titer antibodies that provide short-term protection from disease, but do not induce the liver-resident memory CD8\n                  <jats:sup>+<\/jats:sup>\n                  T cells (Trm) that confer strong PE immunity and long-term protection. In contrast, whole-organism (WO) vaccines, employing for example radiation-attenuated spz (RAS), elicit both high antibody titers and Trm, and have achieved high levels of sterilizing protection. However, they require multiple intravenous (IV) doses, which must be administered at intervals of several weeks, complicating mass administration in the field. Moreover, the quantities of spz required present production difficulties. To reduce reliance on WO while maintaining protection via both antibodies and Trm responses, we have developed an accelerated vaccination regimen that combines two distinct agents in a prime-and-trap strategy. While the priming dose is a self-replicating RNA encoding\n                  <jats:italic>P. yoelii<\/jats:italic>\n                  CS protein, delivered via an advanced cationic nanocarrier (LION\n                  <jats:sup>TM<\/jats:sup>\n                  ), the trapping dose consists of WO RAS. This accelerated regime confers sterile protection in the\n                  <jats:italic>P. yoelii<\/jats:italic>\n                  mouse model of malaria. Our approach presents a clear path to late-stage preclinical and clinical testing of dose-sparing, same-day regimens that can confer sterilizing protection against malaria.\n                <\/jats:p>","DOI":"10.1101\/2023.05.23.541932","type":"posted-content","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T02:56:05Z","timestamp":1684896965000},"source":"Crossref","is-referenced-by-count":0,"title":["Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine"],"prefix":"10.64898","author":[{"given":"Zachary","family":"MacMillen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiara","family":"Hatzakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie J.","family":"Shears","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse H.","family":"Erasmus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit P.","family":"Khandhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Wilder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean C.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Davie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3569-2049","authenticated-orcid":false,"given":"Marion","family":"Avril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023052521301046000_2023.05.23.541932v1.1","unstructured":"WHO | World malaria report 2018 [Internet]. WHO. World Health Organization; 2020 [cited 2020 Nov 23]. Available from: http:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2018\/report\/en\/"},{"key":"2023052521301046000_2023.05.23.541932v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.06.008"},{"key":"2023052521301046000_2023.05.23.541932v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/nature21060"},{"key":"2023052521301046000_2023.05.23.541932v1.4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001685"},{"key":"2023052521301046000_2023.05.23.541932v1.5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061395"},{"key":"2023052521301046000_2023.05.23.541932v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208394"},{"key":"2023052521301046000_2023.05.23.541932v1.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102287"},{"key":"2023052521301046000_2023.05.23.541932v1.8","unstructured":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial - PubMed [Internet]. 2021 [cited 2021 Aug 6]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33964223\/"},{"key":"2023052521301046000_2023.05.23.541932v1.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505819"},{"key":"2023052521301046000_2023.05.23.541932v1.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1715812114"},{"key":"2023052521301046000_2023.05.23.541932v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/srep46621"},{"issue":"1","key":"2023052521301046000_2023.05.23.541932v1.12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12936-020-3141-z","article-title":"Plasmodium falciparum pre-erythrocytic stage vaccine development","volume":"19","year":"2020","journal-title":"Malar J"},{"key":"2023052521301046000_2023.05.23.541932v1.13","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00180-13"},{"issue":"41","key":"2023052521301046000_2023.05.23.541932v1.14","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1016\/j.vaccine.2017.02.040","article-title":"Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants","volume":"35","year":"2017","journal-title":"Vaccine"},{"issue":"12","key":"2023052521301046000_2023.05.23.541932v1.15","doi-asserted-by":"crossref","first-page":"e1010133","DOI":"10.1371\/journal.ppat.1010133","article-title":"Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein","volume":"17","year":"2021","journal-title":"PLoS Pathog"},{"issue":"4","key":"2023052521301046000_2023.05.23.541932v1.16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","article-title":"A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver","volume":"53","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"2023052521301046000_2023.05.23.541932v1.17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12936-020-03181-0","article-title":"Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein","volume":"19","year":"2020","journal-title":"Malar J"},{"key":"2023052521301046000_2023.05.23.541932v1.18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800727"},{"issue":"5","key":"2023052521301046000_2023.05.23.541932v1.19","doi-asserted-by":"crossref","first-page":"109956","DOI":"10.1016\/j.celrep.2021.109956","article-title":"Expeditious recruitment of circulating memory CD8 T cells to the liver facilitates control of malaria","volume":"37","year":"2021","journal-title":"Cell Rep"},{"key":"2023052521301046000_2023.05.23.541932v1.20","doi-asserted-by":"crossref","unstructured":"Hassert M , Arumugam S , Harty JT . Memory CD8+ T cell-mediated protection against liver-stage malaria. Immunol Rev [Internet]. [cited 2023 Apr 19];n\/a(n\/a). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/imr.13202","DOI":"10.1111\/imr.13202"},{"key":"2023052521301046000_2023.05.23.541932v1.21","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2014.00272"},{"issue":"1","key":"2023052521301046000_2023.05.23.541932v1.22","first-page":"e89154","article-title":"Protection against Plasmodium falciparum malaria by PfSPZ Vaccine","volume":"2","year":"2017","journal-title":"JCI Insight"},{"key":"2023052521301046000_2023.05.23.541932v1.23","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-1014"},{"key":"2023052521301046000_2023.05.23.541932v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03684-z"},{"key":"2023052521301046000_2023.05.23.541932v1.25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn9709"},{"key":"2023052521301046000_2023.05.23.541932v1.26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9099"},{"key":"2023052521301046000_2023.05.23.541932v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4110"},{"key":"2023052521301046000_2023.05.23.541932v1.28","doi-asserted-by":"crossref","unstructured":"Itsara LS , Zhou Y , Do J , Grieser AM , Vaughan AM , Ghosh AK . The Development of Whole Sporozoite Vaccines for Plasmodium falciparum Malaria. Front Immunol [Internet]. Frontiers; 2018 [cited 2020 Aug 13];9. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2018.02748\/full","DOI":"10.3389\/fimmu.2018.02748"},{"key":"2023052521301046000_2023.05.23.541932v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30104-4"},{"key":"2023052521301046000_2023.05.23.541932v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00332-7"},{"key":"2023052521301046000_2023.05.23.541932v1.31","first-page":"101579","article-title":"DMID 15-0052 PfSPZ-CVac Study Team. PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial","volume":"52","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2023052521301046000_2023.05.23.541932v1.32","doi-asserted-by":"publisher","DOI":"10.1038\/nri1746"},{"issue":"4","key":"2023052521301046000_2023.05.23.541932v1.33","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.immuni.2019.09.019","article-title":"Liver-Resident Memory CD8+ T Cells Form a Front-Line Defense against Malaria Liver-Stage Infection","volume":"51","year":"2019","journal-title":"Immunity"},{"key":"2023052521301046000_2023.05.23.541932v1.34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800740"},{"key":"2023052521301046000_2023.05.23.541932v1.35","first-page":"tpmd211084","article-title":"Cryopreserved Sporozoites with and without the Glycolipid Adjuvant 7DW8-5 Protect in Prime-and-Trap Malaria Vaccination","year":"2022","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"2023052521301046000_2023.05.23.541932v1.36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41541-021-00345-0","article-title":"Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice","volume":"6","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"1","key":"2023052521301046000_2023.05.23.541932v1.37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41541-022-00577-8","article-title":"mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum","volume":"7","year":"2022","journal-title":"NPJ Vaccines"},{"key":"2023052521301046000_2023.05.23.541932v1.38","unstructured":"The \u201canti-hype\u201d vaccine | Nature Biotechnology [Internet]. 2020 [cited 2020 Nov 23]. Available from: https:\/\/www.nature.com\/articles\/nbt.3812"},{"key":"2023052521301046000_2023.05.23.541932v1.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906"},{"key":"2023052521301046000_2023.05.23.541932v1.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2023052521301046000_2023.05.23.541932v1.41","unstructured":"spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf."},{"key":"2023052521301046000_2023.05.23.541932v1.42","unstructured":"comirnaty-epar-public-assessment-report_en.pdf."},{"key":"2023052521301046000_2023.05.23.541932v1.43","doi-asserted-by":"crossref","unstructured":"Zhao Y , Huang L . Chapter Two - Lipid Nanoparticles for Gene Delivery. In: Huang L , Liu D , Wagner E , editors. Adv Genet [Internet]. Academic Press; 2014 [cited 2020 Nov 23]. p. 13\u201336. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/B978012800148600002X","DOI":"10.1016\/B978-0-12-800148-6.00002-X"},{"key":"2023052521301046000_2023.05.23.541932v1.44","doi-asserted-by":"crossref","unstructured":"Erasmus JH , Khandhar AP , O\u2019Connor MA , Walls AC , Hemann EA , Murapa P , Archer J , Leventhal S , Fuller JT , Lewis TB , Draves KE , Randall S , Guerriero KA , Duthie MS , Carter D , Reed SG , Hawman DW , Feldmann H , Gale M , Veesler D , Berglund P , Fuller DH . An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci Transl Med. 2020 05;12(555). PMCID: PMC7402629","DOI":"10.1126\/scitranslmed.abc9396"},{"issue":"10","key":"2023052521301046000_2023.05.23.541932v1.45","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.ymthe.2018.07.010","article-title":"A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single","volume":"26","year":"2018","journal-title":"Low-Dose Protection against Zika. Mol Ther J Am Soc Gene Ther"},{"key":"2023052521301046000_2023.05.23.541932v1.46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice","volume":"18","year":"2020","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"2023052521301046000_2023.05.23.541932v1.47","unstructured":"COVID-19 shots with Seattle origins reach regulatory milestones in South Korea, India \u2013 GeekWire [Internet]. [cited 2022 Nov 22]. Available from: https:\/\/www.geekwire.com\/2022\/covid-19-shots-with-seattle-origins-reach-regulatory-milestones-in-south-korea-india\/"},{"key":"2023052521301046000_2023.05.23.541932v1.48","unstructured":"HDT Bio\u2019s COVID-19 Vaccine Wins Regulatory Approval in India | Business Wire [Internet]. [cited 2022 Jul 6]. Available from: https:\/\/www.businesswire.com\/news\/home\/20220629005703\/en\/HDT-Bio%E2%80%99s-COVID-19-Vaccine-Wins-Regulatory-Approval-in-India"},{"key":"2023052521301046000_2023.05.23.541932v1.49","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2015.965690"},{"key":"2023052521301046000_2023.05.23.541932v1.50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9099"},{"key":"2023052521301046000_2023.05.23.541932v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2011.05.008"},{"key":"2023052521301046000_2023.05.23.541932v1.52","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241800"},{"key":"2023052521301046000_2023.05.23.541932v1.53","doi-asserted-by":"crossref","unstructured":"Vaughan AM , Sack BK , Dankwa D , Minkah N , Nguyen T , Cardamone H , Kappe SHI . A Plasmodium Parasite with Complete Late Liver Stage Arrest Protects against Preerythrocytic and Erythrocytic Stage Infection in Mice. Infect Immun [Internet]. 2018 Apr 23 [cited 2020 Sep 24];86(5). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5913857\/ PMCID: PMC5913857","DOI":"10.1128\/IAI.00088-18"},{"issue":"13","key":"2023052521301046000_2023.05.23.541932v1.54","doi-asserted-by":"crossref","first-page":"135589","DOI":"10.1172\/jci.insight.135589","article-title":"A replication-competent late liver stage-attenuated human malaria parasite","volume":"5","year":"2020","journal-title":"JCI Insight"},{"key":"2023052521301046000_2023.05.23.541932v1.55","doi-asserted-by":"publisher","DOI":"10.1086\/597121"},{"key":"2023052521301046000_2023.05.23.541932v1.56","doi-asserted-by":"publisher","DOI":"10.1038\/216160a0"},{"key":"2023052521301046000_2023.05.23.541932v1.57","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-197309000-00002"},{"key":"2023052521301046000_2023.05.23.541932v1.58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408442102"},{"key":"2023052521301046000_2023.05.23.541932v1.59","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu281"},{"issue":"Suppl 1","key":"2023052521301046000_2023.05.23.541932v1.60","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1590\/S0074-02762011000900022","article-title":"Induction and maintenance of protective CD8+ T cells against malaria liver stages: implications for vaccine development","volume":"106","year":"2011","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2023052521301046000_2023.05.23.541932v1.61","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2013.20"},{"key":"2023052521301046000_2023.05.23.541932v1.62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065960"},{"key":"2023052521301046000_2023.05.23.541932v1.63","first-page":"tpmd211297","article-title":"Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"2023052521301046000_2023.05.23.541932v1.64","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-1014"},{"issue":"9","key":"2023052521301046000_2023.05.23.541932v1.65","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","article-title":"Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"27","year":"2021","journal-title":"Nat Med"},{"key":"2023052521301046000_2023.05.23.541932v1.66","doi-asserted-by":"publisher","DOI":"10.1038\/nature05361"},{"key":"2023052521301046000_2023.05.23.541932v1.67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"issue":"1","key":"2023052521301046000_2023.05.23.541932v1.68","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s42003-021-02441-2","article-title":"Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration","volume":"4","year":"2021","journal-title":"Commun Biol"},{"key":"2023052521301046000_2023.05.23.541932v1.69","doi-asserted-by":"crossref","first-page":"104196","DOI":"10.1016\/j.ebiom.2022.104196","article-title":"Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in na\u00efve hamsters compared to ancestral vaccine","volume":"83","year":"2022","journal-title":"EBioMedicine"},{"key":"2023052521301046000_2023.05.23.541932v1.70","doi-asserted-by":"publisher","DOI":"10.1086\/519742"},{"issue":"1","key":"2023052521301046000_2023.05.23.541932v1.71","first-page":"3950","article-title":"Innate immunity limits protective adaptive immune responses against pre-erythrocytic malaria parasites. Nat Commun","volume":"10","year":"2019","journal-title":"Nature Publishing Group"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.05.23.541932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:41:26Z","timestamp":1768452086000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.05.23.541932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":71,"URL":"https:\/\/doi.org\/10.1101\/2023.05.23.541932","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41541-023-00799-4","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,5,23]]},"subtype":"preprint"}}